Elucid enables precision medicine for cardiovascular disease by applying A.I to medical image analysis validated against true biology.
Elucid has raised $36.5M in total funding. The most recent round was Series D. The last funding was announced in October 2025.
Elucid's investors include National Science Foundation, Elevage Medical Technologies, Aphelion Capital, Sand Hill Angels, BlueStone Venture Partners.
Elucid is headquartered in Boston, United States.
Elucid enables precision medicine for cardiovascular disease by applying A.I to medical image analysis validated against true biology.
Elucid is at the Series D stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Elucid — Funding & Investors." VCBacked, October 22, 2025, https://www.vcbacked.co/company/elucid. Accessed September 15, 2026.
VCBacked. (2025). Elucid — Funding & Investors. Retrieved September 15, 2026, from https://www.vcbacked.co/company/elucid
{{cite web |title=Elucid — Funding & Investors |url=https://www.vcbacked.co/company/elucid |website=VCBacked |access-date=September 15, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated